Cipla Share Price

1,376.700.21 (0.02%)

Live
As On: 10 Jun, 2026, 09:16 AM IST
As On: 10 Jun, 2026, 09:15 AM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Open	1,374.00
High	1,377.60
Low	1,371.10
Prev Close	1,376.50
Volume	20,398
VWAP(₹)	1,374.23

Share Price	Value
Today/Current/Last	1,376.701,372.25
Previous Day	1,376.501,376.75

Cipla Share Recommendations

Mean recosCurrent

BUY

37 Analysts

Strong
SellSellHoldBuyStrong
Buy

Analyst Trends

Ratings	Current	1W Ago	1M Ago	3M Ago
Strong Buy	7	7	6	5
Buy	15	15	13	15
Hold	9	9	11	8
Sell	4	4	5	7
Strong Sell	2	2	2	2
# Analysts	37	37	37	37

Recent Recos

Target₹1735
OrganizationAxis Securities
BUY

Target₹1830
OrganizationMotilal Oswal Financial Services
BUY

Target₹1700
OrganizationMotilal Oswal Financial Services
BUY

View all Stock Recommendations

News & Analysis

View all Cipla Share News & Announcements

Financials

Income (P&L)

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	6,689.36	7,280.82	7,858.39	7,216.03	7,019.15
Total Income Growth (%)	-8.12	-7.35	8.90	2.80	-3.78
Total Expenses	5,969.17	6,373.68	5,991.68	5,432.05	5,500.83
Total Expenses Growth (%)	-6.35	6.38	10.30	-1.25	2.55
EBIT	720.19	907.14	1,866.71	1,783.98	1,518.32
EBIT Growth (%)	-20.61	-51.40	4.64	17.50	-21.36
Profit after Tax (PAT)	554.64	675.80	1,351.17	1,297.62	1,221.84
PAT Growth (%)	-17.93	-49.98	4.13	6.20	-22.20
EBIT Margin (%)	10.77	12.46	23.75	24.72	21.63
Net Profit Margin (%)	8.29	9.28	17.19	17.98	17.41
Basic EPS (₹)	6.87	8.37	16.73	16.07	15.13

	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025
Total Income	4,390.20	4,914.78	5,480.38	5,317.24	5,091.26
Total Income Growth (%)	-10.67	-10.32	3.07	4.44	-1.32
Total Expenses	3,860.98	4,174.58	3,844.39	3,567.41	3,332.22
Total Expenses Growth (%)	-7.51	8.59	7.76	7.06	-3.46
EBIT	529.22	740.20	1,635.99	1,749.83	1,759.04
EBIT Growth (%)	-28.50	-54.76	-6.51	-0.52	2.99
Profit after Tax (PAT)	384.64	616.88	1,210.53	1,303.13	1,485.40
PAT Growth (%)	-37.65	-49.04	-7.11	-12.27	3.29
EBIT Margin (%)	12.05	15.06	29.85	32.91	34.55
Net Profit Margin (%)	8.76	12.55	22.09	24.51	29.18
Basic EPS (₹)	4.76	7.64	14.99	16.13	18.39

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	29,044.60	28,409.49	26,520.66	23,228.57	22,044.25
Total Revenue Growth (%)	2.24	7.12	14.17	5.37	13.48
Total Expenses	23,545.06	21,588.68	20,623.94	19,007.80	18,368.86
Total Expenses Growth (%)	9.06	4.68	8.50	3.48	13.84
Profit after Tax (PAT)	3,879.23	5,272.52	4,121.55	2,801.91	2,516.75
PAT Growth (%)	-26.43	27.93	47.10	11.33	4.65
Operating Profit Margin (%)	19.72	24.98	23.22	19.03	17.37
Net Profit Margin (%)	13.77	19.13	15.99	12.31	11.56
Basic EPS (₹)	48.03	65.29	51.05	34.72	31.20

	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Revenue	20,102.60	20,029.57	17,645.00	16,247.39	13,758.49
Total Revenue Growth (%)	0.36	13.51	8.60	18.09	-2.64
Total Expenses	15,222.29	13,855.41	12,698.03	12,620.95	10,212.26
Total Expenses Growth (%)	9.87	9.11	0.61	23.59	-5.27
Profit after Tax (PAT)	3,515.18	5,157.65	4,077.25	2,513.47	2,957.93
PAT Growth (%)	-31.85	26.50	62.22	-15.03	19.84
Operating Profit Margin (%)	25.81	32.49	29.96	23.13	27.29
Net Profit Margin (%)	18.52	27.08	24.59	15.91	22.59
Basic EPS (₹)	43.52	63.87	50.51	31.15	36.67

All figures in Rs Cr, unless mentioned otherwise

Insights

Quarterly Topline Performance
Company witnessed QoQ revenue decline of 8.12%, which is lowest in the last 3 years. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 19.05% towards employee cost in the year ending Mar 31, 2026. (Source: Consolidated Financials)

View Details

Balance Sheet

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	42,495.98	37,387.04	32,717.82	29,463.28	27,101.12
Total Assets Growth (%)	13.67	14.27	11.05	8.72	7.75
Total Liabilities	7,975.74	6,097.79	5,915.49	5,749.74	5,983.74
Total Liabilities Growth (%)	30.80	3.08	2.88	-3.91	-8.87
Total Equity	34,520.24	31,289.25	26,802.33	23,713.54	21,117.38
Total Equity Growth (%)	10.33	16.74	13.03	12.29	13.62
Current Ratio (x)	3.44	4.25	3.71	3.38	3.00
Total Debt to Equity (x)	0.01	0.00	0.01	0.02	0.04
Contingent Liabilities	3,546.05	3,697.15	4,629.56	1,095.87	1,291.24

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Total Assets	38,493.09	35,565.72	31,053.23	27,596.47	25,449.05
Total Assets Growth (%)	8.23	14.53	12.53	8.44	10.82
Total Liabilities	4,291.98	3,466.48	3,079.31	2,958.38	2,935.50
Total Liabilities Growth (%)	23.81	12.57	4.09	0.78	-3.32
Total Equity	34,201.11	32,099.24	27,973.92	24,638.09	22,513.55
Total Equity Growth (%)	6.55	14.75	13.54	9.44	12.98
Current Ratio (x)	4.63	5.78	5.21	4.95	4.41
Total Debt to Equity (x)	0.00	0.00	0.00	0.00	0.00
Contingent Liabilities	2,368.01	2,947.43	2,298.65	897.09	975.31

All figures in Rs Cr, unless mentioned otherwise

View Details

Cash Flows

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	3,940.02	5,004.98	4,133.91	3,237.65	3,325.90
Net Cash used in Investing Activities	-2,326.13	-3,691.14	-2,988.03	-2,388.51	-1,871.88
Net Cash flow from Financing Activities	-1,233.65	-1,292.79	-1,200.43	-958.29	-1,599.79
Net Cash Flow	472.74	30.31	-48.99	-96.78	-132.32
Closing Cash & Cash Equivalent	1,015.39	542.65	512.34	561.33	658.11
Closing Cash & Cash Equivalent Growth (%)	87.12	5.92	-8.73	-14.71	-17.04
Total Debt/ CFO (x)	0.07	0.02	0.06	0.16	0.25

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Net Cash flow from Operating Activities	2,831.69	3,300.99	3,726.77	3,035.05	2,773.43
Net Cash used in Investing Activities	-1,344.09	-2,308.53	-2,882.82	-2,757.95	-2,463.73
Net Cash flow from Financing Activities	-1,321.90	-1,073.93	-708.83	-424.77	-426.72
Net Cash Flow	166.06	-81.78	135.04	-147.81	-117.43
Closing Cash & Cash Equivalent	248.80	82.74	164.52	29.48	177.29
Closing Cash & Cash Equivalent Growth (%)	200.70	-49.71	458.07	-83.37	-39.84
Total Debt/ CFO (x)	0.00	0.00	0.00	0.00	0.00

All figures in Rs Cr, unless mentioned otherwise

Insights

Decrease in Cash from Investing
Company has used Rs 2326.13 cr for investing activities which is an YoY decrease of 36.98%. (Source: Consolidated Financials)

View Details

Ratios

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	11.26	16.90	15.43	11.96	12.07
Return on Capital Employed (%)	15.65	21.57	21.79	17.78	17.04
Return on Assets (%)	9.12	14.10	12.59	9.50	9.28
Interest Coverage Ratio (x)	124.38	128.85	78.30	50.23	45.45
Asset Turnover Ratio (x)	0.71	0.79	0.83	0.58	0.52
Price to Earnings (x)	25.51	22.12	29.33	25.97	32.68
Price to Book (x)	2.87	3.73	4.52	3.11	3.94
EV/EBITDA (x)	14.46	14.50	17.07	13.08	16.83
EBITDA Margin (%)	24.02	29.00	27.30	24.18	22.21

Annual	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Return on Equity (%)	10.27	16.06	14.57	10.20	13.13
Return on Capital Employed (%)	14.15	19.11	17.61	14.67	15.72
Return on Assets (%)	9.13	14.50	13.12	9.10	11.62
Interest Coverage Ratio (x)	287.98	447.59	274.31	157.27	149.76
Asset Turnover Ratio (x)	0.51	0.57	0.57	0.60	0.54
Price to Earnings (x)	28.17	22.62	29.67	28.99	27.86
Price to Book (x)	2.89	3.63	4.31	2.95	3.65
EV/EBITDA (x)	17.68	17.17	21.66	16.88	20.02
EBITDA Margin (%)	29.28	35.51	33.51	26.91	30.80

Found Financials useful?

5 Days	14 Days	28 Days
27.90	29.71	29.66

Peer Comparison

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Cipla	28.66	3.22	11.26	15.65	9.12	7.65	19.72	13.74	48.03	3.44	0.01	0.07
Divis Labs	69.81	10.70	15.32	19.37	12.81	10.79	33.00	24.31	96.75	5.43	0.00	0.00
Torrent Pharma	69.99	8.61	25.78	9.30	4.88	12.70	23.93	15.29	63.92	1.13	1.76	4.90
Cadila Healthcare	22.07	3.76	18.58	20.64	9.61	16.47	27.90	18.51	50.09	1.27	0.43	5.56
Dr. Reddys	25.23	2.77	11.07	13.90	7.21	10.76	17.07	12.29	50.41	1.80	0.17	1.11
Add More

Annual Ratios (%)

Choose from Peers

Lupin
Mankind Pharma
Aurobindo Pharma
Biocon
Alkem Labs

Choose from Stocks

Stock Performance

CHART
TABLE

1D
1W
1M
3M
6M
1Y
5Y

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Cipla Stock Performance	-0.83	-4.19	11.68	2.64	-7.14	50.23	48.51
Divis Labs Stock Performance	3.56	-2.43	7.43	7.34	3.07	117.96	65.52
Torrent Pharma Stock Performance	1.42	1.57	8.15	5.45	36.00	169.14	229.14
Cadila Healthcare Stock Performance	1.66	11.49	19.06	22.74	24.27	123.49	80.31
Dr. Reddys Stock Performance	-0.56	-2.69	3.92	-0.93	3.58	44.41	21.59
Add More

Found Peer Comparison useful?

Category	No. of Shares	Percentage	% Change QoQ
Promoters	23,52,87,003	29.21 %	0.00
Pledge	0	0.00 %	0.00
FII	18,16,69,955	22.55 %	-1.37
DII	25,48,07,353	31.65 %	1.27
MF	15,02,64,666	18.66 %	-0.55
Others	13,60,18,320	16.59 %	0.10

Category	Mar 2026	Dec 2025	Sep 2025	Jun 2025
Promoters	29.21	29.21	29.21	29.19
Pledge	0.00	0.00	0.00	0.00
FII	22.55	23.93	24.54	25.24
DII	31.65	30.37	29.89	28.87
Mutual Funds	18.66	19.21	20.23	20.44
Others	16.59	16.48	16.36	16.70

Mutual Funds Ownership

MF Ownership as on 30 April 2026

HDFC Flexi Cap Direct-G
Equity: Flexi Cap
5
- 2,750.16
  Amount Invested (in Cr.)
- 2.74%
  % of AUM
- 0.00
  % Change (MoM basis)
Parag Parikh Flexi Cap Direct-G
Equity: Flexi Cap
5
- 1,878.56
  Amount Invested (in Cr.)
- 1.33279459%
  % of AUM
- 8.09
  % Change (MoM basis)
HDFC Focused Direct-G
Equity: Flexi Cap
5
- 914.25
  Amount Invested (in Cr.)
- 3.49%
  % of AUM
- -3.94
  % Change (MoM basis)

View all Mutual Fund Schemes

Cipla Futures & Options

Options

Type
Expiry Month
Strike Price

Date	Price	Open Interest
30-06-2026Current	30.05-7.75 (-20.50%)	1,07,2500 (0.00%)
37.50 Open	39.45 High	28.25 Low
37.80 Close	162 Contracts Traded	2,294.63 Turnover (₹ Lakhs)

Open Interest as of 09 Jun 2026

Futures

Expiry MonthPlease select expiry month:

Date	Price	Open Interest
30-06-2026Current	1,384.90-11.20 (-0.80%)	1,46,29,5001,95,750 (1.36%)
1,391.30 Open	1,402.30 High	1,380.80 Low
1,396.10 Prev Close	2,521 Contracts Traded	13,135.67 Turnover (₹ Lakhs)

Open Interest as of 09 Jun 2026

Corporate Actions

Recent
General Meeting
-
May 13, 2026
Final
650%
May 13, 2026
Board Meeting
Audited Results & Final Dividend
Apr 01, 2026

Board Meetings

Announced on	Meeting on
Apr 01, 2026	May 13, 2026
Audited Results & Final Dividend
Dec 23, 2025	Jan 23, 2026
Quarterly Results
Sep 24, 2025	Oct 30, 2025
Quarterly Results
Jul 01, 2025	Jul 25, 2025
Quarterly Results
Apr 07, 2025	May 13, 2025
Audited Results & Final Dividend

Dividends
Announced on Ex-Date Dividend%
May 13, 2026 Jun 05, 2026 650%
May 14, 2025 Jun 27, 2025 150%
May 13, 2025 Jun 27, 2025 650%
May 10, 2024 Aug 02, 2024 650%
May 12, 2023 Jul 21, 2023 425%

Announced on	Ex-Date	Dividend%
May 13, 2026	Jun 05, 2026	650%
May 14, 2025	Jun 27, 2025	150%
May 13, 2025	Jun 27, 2025	650%
May 10, 2024	Aug 02, 2024	650%
May 12, 2023	Jul 21, 2023	425%

Bonus

Announced on	Ex-Date
Feb 11, 2006	Apr 24, 2006
Bonus Ratio: 3 share(s) for every 2 shares held
Oct 07, 1999	Oct 18, 1999
Bonus Ratio: 2 share(s) for every 1 shares held
Mar 24, 1994	Apr 04, 1994
Bonus Ratio: 5 share(s) for every 1 shares held
Sep 30, 1992	Oct 06, 1992
Bonus Ratio: 1 share(s) for every 1 shares held
Oct 11, 1988	-
Bonus Ratio: 1 share(s) for every 1 shares held

Splits
Announced on Ex-Date
Mar 23, 2004 May 11, 2004
Split: Old FV10.0| New FV:2.0
Jul 29, 1994 Jul 29, 1994
Split: Old FV100.0| New FV:10.0
Rights
Announced on Ex-Date
May 03, 1995 Feb 03, 1995
Rights ratio: 4 share for every 50 held at a price of Rs 670.0
AGM/EGM Meetings
Announced on Meeting on
May 13, 2026 Jun 25, 2026
-
Feb 24, 2026 Mar 30, 2026
-
May 13, 2025 Jul 16, 2025
-
Sep 17, 2024 Oct 15, 2024
-
May 10, 2024 Aug 20, 2024
-

Announced on	Ex-Date
Mar 23, 2004	May 11, 2004
Split: Old FV10.0\| New FV:2.0
Jul 29, 1994	Jul 29, 1994
Split: Old FV100.0\| New FV:10.0

Announced on	Ex-Date
May 03, 1995	Feb 03, 1995
Rights ratio: 4 share for every 50 held at a price of Rs 670.0

Announced on	Meeting on
May 13, 2026	Jun 25, 2026
-
Feb 24, 2026	Mar 30, 2026
-
May 13, 2025	Jul 16, 2025
-
Sep 17, 2024	Oct 15, 2024
-
May 10, 2024	Aug 20, 2024
-

About Cipla

Cipla Ltd., incorporated in the year 1935, is a Large Cap company (having a market cap of Rs 1,11,191.28 Crore) operating in Pharmaceuticals sector.

Cipla Ltd. key Products/Revenue Segments include Pharmaceuticals, Royalty Income, Other Operating Revenue, Export Incentives and Scrap for the year ending 31-Mar-2026.

For the quarter ended 31-03-2026, the company has reported a Consolidated Total Income of Rs 6,689.36 Crore, down 8.12 % from last quarter Total Income of Rs 7,280.82 Crore and down 4.70 % from last year same quarter Total Income of Rs 7,019.15 Crore. Company has reported net profit after tax of Rs 550.11 Crore in latest quarter.

The company’s top management includes Dr.Y K Hamied, Mr.P R Ramesh, Mr.Achin Gupta, Mr.Abhijit Joshi, Mr.Adil Zainulbhai, Mr.Kamil Hamied, Dr.Balram Bhargava, Dr.Mandar Vaidya, Ms.Maya Hari, Ms.Sharmila Paranjpe, Mr.Ashish Adukia, Mr.Rajendra Chopra. Company has Walker Chandiok & Co. LLP as its auditors. As on 31-03-2026, the company has a total of 80.78 Crore shares outstanding.

Cipla Share Price Today is Rs. 1376.70. On previous day, the Cipla Share Price (NSE) closed at Rs. 1387.9, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 29.21% of the stake in Cipla shares, out of which 0.0% was pledged. On the same date, foreign institutional investors' (FII) holdings of Cipla stocks was 22.55% as compared to 23.93% in Dec 2025 with decrease of 1.38%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 31.65% as compared to 30.37% in Dec 2025 with increase of 1.28%. Out of the total DII holdings in Cipla shares 18.66% was held by mutual funds. The rest including public held is 16.59%. Cipla stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Cipla Dividend: Ever since 1935, Cipla dividends has been paid out around 33 times. As on 10 Jun, 2026, 09:16 AM IST, The overall dividend yield for Cipla stands at 0.94%. The last dividend paid was on June 5, 2026 (Rs. 13.0). The Earnings Per Share (EPS) for quarter ending 31st Mar 2026 is Rs. 48.02.

Cipla Bonus: The most recent bonus issue had been in year April 24, 2006 around 20 years ago at 2 : 3 ratio. The first bonus issue was announced in Aug 1980.

Stock Forecast:
After showing 6766.3 Cr. of sales and 8.47% of quarterly net loss, there have been multiple ups and downs in the Cipla stock prices in the past few weeks. For example, Cipla stock price on 2nd of June 2026 was around Rs. 1379.3. Cipla share price now stands at an average of Rs. 1376.70. Judging by last week's performance, stock is in up trend.

Cipla has a median target price of Rs. 1463.11 in 12 months by 36 analysts. They have provided a high estimate of Rs. 1820.0 and low estimate of Rs. 1080.0 for Cipla share.

Historical Prices and Performance:
Cipla, incorporated in 1935 is a Large Cap company (with a market cap of Rs. 111191.28) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Cipla stock was 11.26%, 16.9%, 15.43%, 11.96% and 12.07% respectively.
The Cipla share gave a 3 year return of 42.02% as compared to Nifty 50 which gave a return of 25.2%.
Cipla announced 650.0% final dividend on June 5, 2026.

Key Metrics:
PE Ratio of Cipla is 28.66
Prices/Sales Ratio of Cipla is 3.51
Price/Book Ratio of Cipla is 3.22

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. For Cipla, major competitors and peers include Divis Labs, Torrent Pharma, Cadila Healthcare and Dr. Reddys. As of Dec 2025, the dividend yield of Cipla stands at 0.94% while Divis Labs, Torrent Pharma, Cadila Healthcare and Dr. Reddys stand at 0.44%, 0.85%, 0.09% and 0.63% respectively. The PE ratio and PB Ratio of the company are among its competitors stand at 28.66 and 3.22 respectively.

Recommendations:
The current total number of analysts covering the stock stands at 37, Three months ago this number stood at 37. Out of total, 7 analyst have a'Strong Buy' reco, 15 analyst have a'Buy' reco, 9 analyst have a'Hold' reco, 4 analyst have a'Sell' reco.

Mean recommendations by 37 analyst stand at'Buy'.

Leadership of Cipla :
Rajendra Chopra is Co. Secretary & Compl. Officer
Ashish Adukia is Global Chief Financial Officer
Vijayasarathi Ramaswami is Global Head
Sneha Hiranandani is Chief Information Officer
Sai Mungara is Global Head
Arun Kakatkar is Global Chief People Officer
Prabhakaran Nair is Chief Manufacturing Officer
Jaideep Gogtay is Chief Medical Officer
Y K Hamied is Chairman
P R Ramesh is Vice Chairman & Independent Director
Achin Gupta is Managing Director & Global CEO
Abhijit Joshi is Non Executive Director
Adil Zainulbhai is Non Executive Director
Kamil Hamied is Non Executive Director
Maya Hari is Independent Director
Balram Bhargava is Independent Director
Mandar Vaidya is Independent Director
Sharmila Paranjpe is Independent Director

Industry

Pharma - Indian

Key Indices Listed On

Nifty 50, Nifty 100, Nifty 200, Nifty 500, BSE 500

Address

Cipla House,Peninsula Business Park,Ganpatrao Kadam Marg,Mumbai, Maharashtra - 400013

Contact

cosecretary@cipla.com

http://www.cipla.com

PE Ratio(x)	28.66
EPS - TTM(₹)	48.02
MCap(₹ Cr.)	1,11,191
MCap Rank	5
PB Ratio(x)	3.22
Div Yield(%)	0.94
Face Value(₹)	2.00
52W High(₹)	1,673.00
52W Low(₹)	1,165.70
MCap/Sales	3.51
Beta(1 Month)	-0.43
BV/Share(₹)	427.35

PE Ratio(x)	28.63
EPS - TTM(₹)	48.02
MCap(₹ Cr.)	1,11,211
MCap Rank	5
PB Ratio(x)	3.22
Div Yield(%)	0.95
Face Value(₹)	2.00
52W High(₹)	1,672.20
52W Low(₹)	1,165.55
MCap/Sales	3.51
Beta(1 Month)	-0.40
BV/Share(₹)	427.35

1 Day	0.02%
1 Month	2.2%
3 Months	3.24%
1 Year	-8.88%
3 Years	42.04%
5 Years	41.32%

1 Day	-0.32%
1 Month	1.82%
3 Months	2.94%
1 Year	-9.16%
3 Years	41.67%
5 Years	40.83%

R1	1392.33	Pivot 1382.97	S1	1367.13
R2	1408.17		S2	1357.77
R3	1433.37		S3	1332.57

Cipla Share Price

Key Metrics